We are committed to patients with hemophilia and the bleeding disorders community.

Ongoing focus.

Two buildings icon

At Novo Nordisk, we believe that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way.

Product portfolio.

Vials icon

We aspire to be a respected leader in the health care industry, helping patients with treatments for:

  • FVII deficiency
  • FVIII deficiency
  • FVIII deficiency with inhibitors
  • FIX deficiency with inhibitors
  • FXIII deficiency
  • Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets
  • Acquired hemophilia

Environmental awareness.

Tree icon

We also strive to minimize the environmental impact of our activities. Our facilities in Denmark supply quality products in a socially responsible and environmentally sound way, using 100% renewable energy.1 

The Triple Bottom Line.

The Triple Bottom Line (TBL) is the Novo Nordisk way of doing business. We believe that a healthy economy, environment, and society are fundamental to long-term business success. We are one of only four companies in the world who have incorporated our philosophy into our company bylaws.

Social impact.

Social responsibility is about caring for people. This applies to the people who depend on our products, as well as to our employees. We work to continuously integrate social, health, and safety considerations into our daily business.


Environmental responsibility.

Environmental soundness addresses our impact on the external environment – and we've taken a concerted approach to ensure that our efforts to be green pay off.

The campus of our LEED Silver certified U.S. Headquarters demonstrates our approach to being responsible stewards of our environment, driven by the company’s commitment to help people live healthy lives, and consistent with Novo Nordisk's TBL business model.

Our campus utilized recycled and locally-sourced materials, and is fully powered by renewable energy from wind, solar, and hydro sources—a feature that is expected to lead to a 30 percent reduction in energy costs.


Financial performance.

Economic viability is about managing the business in a way that secures growth and value creation, and delivers competitive performance in these areas. Investing in our employees contributes to our award-winning workplace and supports our goal of delivering innovative achievements.

Novo Nordisk Inc. has been ranked in Fortune Magazine's Best Places to Work listing every year since 2009. Most recently, Novo Nordisk was presented with the New Good Neighbor Award by the New Jersey Business & Industry Association. This award was based on a variety of factors, including economic benefit/job creation, architectural merit, and community involvement.

Novo Nordisk is also committed to investing in Research and Development. In 2016, 13% of sales went towards funding R&D projects across the organization.

Selected Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Indications and Usage

Novoeight® (Antihemophilic Factor [Recombinant]) is indicated for use in adults and children with hemophilia A for control and prevention of bleeding, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

Novoeight® is not indicated for the treatment of von Willebrand disease.

Important Safety Information

Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins.

Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment.

Development of activity-neutralizing antibodies (inhibitors) may occur.  If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures factor VIII inhibitor concentration.

The most frequently reported adverse reactions (≥0.5%) were injection site reactions, increased hepatic enzymes, and pyrexia.

Please click here for Prescribing Information.

Reference

  1. Data on file. Novo Nordisk Inc., Plainsboro NJ.